Key Summary Points {#d29e383}
==================

**Why carry out this study?**A calcineurin inhibitor (CNI) is considered essential after lung transplantation (LTx) but few randomized controlled trials (RCT) exploring the differences between cyclosporine and tacrolimus exist in LTx.Therefore, we wanted to test whether chronic lung allograft dysfunction (CLAD) would be more prevalent with cyclosporine or tacrolimus in a RCT.The ScanCLAD study is an investigator initiated, pragmatic, controlled, randomized, open-label, multi-center study evaluating if an immunosuppressive protocol based on ATG-induction, once daily tacrolimus-dose, mycophenolate mofetil and corticosteroid reduces the incidence of CLAD after LTx, compared to a cyclosporine-based protocol with all other immunosuppressive and prophylactic drugs being identical between groups.**What was learned from the study?**The ScanCLAD study is enrolling and investigates which CNI is to be preferred from a CLAD perspective after LTx.The ScanCLAD study is designed with more than 10 sub-studies addressing other important and unresolved issues in LTx.

Introduction {#Sec1}
============

A calcineurin inhibitor (CNI) is considered essential after lung transplantation (LTx). Both cyclosporine and tacrolimus are used as CNI after LTx. In Scandinavia we have used cyclosporine for a long time, and still do, with good results in LTx \[[@CR1], [@CR2]\]. Few randomized controlled trials (RCT) exploring the differences between cyclosporine and tacrolimus exist in LTx \[[@CR3]\], and despite this most centers around the world have switched to tacrolimus \[[@CR4]\].

Chronic rejection after LTx is characterized by a decline in lung function and was previously considered equivalent to bronchiolitis obliterans syndrome (BOS). Nowadays chronic rejection is referred to as chronic lung allograft dysfunction (CLAD) \[[@CR5]\]. CLAD includes the older description BOS characterized by small airway fibrosis and obstructive lung physiology and a restrictive allograft syndrome (RAS) characterized by parenchymal/pleural fibrosis and a restrictive physiology. The definition of both CLAD and RAS has recently been updated \[[@CR6], [@CR7]\].

Therefore, in a regular clinical setting where most adult patients undergoing LTx would be eligible for inclusion, we wanted to test whether CLAD would be more prevalent with cyclosporine or tacrolimus.

Methods {#Sec2}
=======

Study Aim {#Sec3}
---------

The aim of the study is to evaluate whether immunosuppression based on a once-daily tacrolimus dose regimen (Advagraf^®^), with anti-thymocyte globulin (Thymoglobulin^®^) induction, mycophenolate mofetil (MMF), and corticosteroids (CS), reduces the cumulative incidence of CLAD after de novo LTx at 36 months, in comparison with a twice-daily cyclosporine-based protocol, with otherwise identical treatment between groups.

Study Design {#Sec4}
------------

This is an investigator-initiated, prospective, Scandinavian (multinational), multicenter, randomized, controlled, parallel group, and open-label study in de novo lung transplant recipients. Patients fulfilling all of the inclusion and none of the exclusion criteria will be randomized to one of the two treatment groups. Enrollment will be continued until the required sample size is achieved. This multicenter study was first approved by the Ethics Review Board (D.nr 154-16) at the University of Gothenburg as well as by the Medical Product Agency in Sweden (EUDRACT number 2015-004137-27, D.nr 5.1 2016-31518), and subsequently by the corresponding authorities in Denmark, Finland, and Norway. Therefore, ethics committees (EC) of all the Scandinavian countries have approved the final study protocol, including the final version of the informed consent form, and the following amendments of the protocol, including all substudies. In addition, medical product agencies in all four participating countries have approved the study. Written informed consent will be obtained before any study-related procedures are implemented. The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH--GCP and applicable local regulatory requirements. The study was registered at ClinicalTrial.gov (NCT02936505) well before the first patient was included in the study.

Study Objectives and Endpoints {#Sec5}
------------------------------

The primary objective is to compare the efficacy between treatment regimes by assessing the difference in CLAD incidence at 36 months after LTx.

Secondary endpoints are outlined in Table [1](#Tab1){ref-type="table"}. Many of these are the basis for separate substudies.Table 1Secondary objectivesTo compare the efficacy between treatment regimes by assessing the difference in  Renal function evaluated by mGFR at 3 months after LTx  The composite measure of freedom from allograft rejection, CLAD, graft survival, and patient survival at 12, 24, and 36 months after transplantation  The cumulative incidence of PGD at 72 h  Patient survival at 1 and 3 years  The cumulative incidence of acute allograft rejection and CLAD at 6 months, 1 year, and 3 years  The cumulative incidence of BOS and RAS at 6 months, 1 year, and 3 years  Development of DSA at 12, 24, and 36 months  Renal function evaluated by mGFR, by iohexol or Cr-EDTA clearance, at 12, 24, and 36 months  Renal function evaluated by cGFR, by three different formulas, at 3, 12, 24, and 36 months  The cumulative incidence of PTDM at 6, 12, 24, and 36 months after transplantation  Use of antidiabetic medication at 6, 12, 24, and 36 months  Incidence and number of antihypertensive and lipid-lowering drugs at 12, 24, and 36 months  Development and magnitude of proteinuria at 12, 24, and 36 months  Lipid profile at 12, 24, and 36 months  Incidence of CMV that required treatment (CMV infection or CMV syndrome)  Cumulative incidence of malignancy stratified by PTLD and all other cancers, at 36 months  Safety and tolerability  Quality of life, assessed by EQ 5D3L and SGRQ, both self-administered, pre-transplant and at 12, 24, and 36 months  Define the pharmacokinetics of tacrolimus in patients without CF (*n* = 12) and all included patients with CF (*n* = 15--20) undergoing primary lung transplantation treated with Advagraf^®^-based immunosuppression  Immunological equipotency of tacrolimus and cyclosporine in vivo and in vitro  Occurrence of treatment failures up to or at 36 months; defined as a composite endpoint of graft loss, death, loss to follow-up or discontinuation due to lack of efficacy or toxicity (at least one condition must be present)  Recovery of right heart function irrespective of diagnosis in patients with PAH (categories 1--5 according to WHO 1--5)*BOS* bronchiolitis obliterans syndrome, *CF* cystic fibrosis,*cGFR* calculated glomerular filtration rate, *CLAD* chronic lung allograft dysfunction,*CMV* cytomegalovirus,*DSA*donor-specific antibodies, *ISHLT* International Society of Heart and Lung Transplantation, *LTx*lung transplantation,*mGFR* measured glomerular filtration rate, *PAH* pulmonary arterial hypertension, *RAS* restrictive allograft syndrome,*PGD* primary graft dysfunction,*PTDM* post-transplantation diabetes mellitus,*PTLD* post-transplant lymphoproliferative disorder, *SGRQ* St Georges Respiratory Questionnaire, *WHO* World Health Organization

Study Population {#Sec6}
----------------

The study population will consist of a representative group (*n* = 242) of de novo lung transplant patients who fulfill the requirements according to inclusion and exclusion criteria (Table [2](#Tab2){ref-type="table"}). The intention is that it will be possible for most patients eligible for LTx in Scandinavia to be included in the study, with the exception of those undergoing re-transplantation, single lung transplantation, and recipients under the age of 18. The patients are randomized immediately prior to transplantation to receive a standard immunosuppressive protocol of cyclosporine, MMF and CS---group A, or a combination of tacrolimus, MMF, and CS---group B (Fig. [1](#Fig1){ref-type="fig"}). The patients will be recruited from all five Scandinavian centers for lung transplantation: Copenhagen, Denmark; Gothenburg, Sweden; Helsinki, Finland; Lund, Sweden; and Oslo, Norway. Since the study is designed as an "all in study" (however, pediatrics and re-transplantations are excluded), the expected inclusion time was calculated to be 2 years since the annual volume is approximately 140 LTx (mean of 142 LTx during 2012--2016, and stratified by center: Gothenburg 43; Lund 16; Oslo 32; Helsinki 20; and Copenhagen 31) among Scandinavian institutions.Table 2Inclusion and exclusion criteriaInclusion criteria Male or female lung recipients 18--70 years of age undergoing primary double (including size reduction) lung transplantation Patient willing and capable of giving written informed consent for study participation and anticipated to be able to participate in the study for 36 monthsExclusion criteria Recipients of multiorgan transplant, and/or previously transplanted with any organ, including previous lung transplantation Patients with hypersensitivity to or other reasons to not be able to take the immunosuppressive drugs used in the study Donor lung cold ischemic time \> 12 h Patients who previously have been treated with anti-thymocyte globulin preparations (e.g., ATG-Fresenius^®^, Thymoglobulin^®^) Patients who are recipients of ABO-incompatible transplants Patients with platelet count \< 50,000/mm^3^ at the evaluation before transplantation Patients who are unlikely to comply with the study requirements Patients, and/or those receiving organs from donors, who are positive for HIV, hepatitis B surface antigen, or hepatitis C virus Patients with donor older than 75 years Patient who have received an unlicensed drug or therapy within 1 month prior to study entry or if such therapy is to be instituted post-transplantation Patient unable to participate in the study for the full 36-month period Patients with any past (within the past 3 years (low-risk malignancy) to 5 years (high-risk malignancy)) or present malignancy (other than excised basal cell carcinoma) Women capable of becoming pregnant must have a negative pregnancy test prior to randomizationFig. 1Design of the ScanCLAD study.*LTx* lung transplantation,*CNI* calcineurin inhibitor,*CyA* cyclosporine,*BID* twice daily,*MMF* mycophenolate mofetil,*CS* corticosteroids,*Tac* tacrolimus,*OD* once daily

Substudies {#Sec7}
----------

The ScanCLAD study includes a number of separate substudies addressing important and unanswered questions, which are of interest regardless of the outcome of the main study. All substudies are shown in Table [3](#Tab3){ref-type="table"}. Each substudy has its own responsible principle investigator (PI), and most include patients from all sites. The substudies have separate protocols and budgets.Table 3Substudies of the main ScanCLAD studyDonor-specific antibodies in chronic lung allograft dysfunctionPTDM in lung transplantationEquipotency of tacrolimus and cyclosporine in vivo and in vitroQuality of life after lung transplantation in ScandinaviaCytomegalovirus as a risk factor for CLAD and its subtypes BOS and RASImaging in primary graft dysfunctionClinical pharmacokinetics of once-daily prolonged release tacrolimus in cystic fibrosis compared to non-cystic fibrosis lung transplant recipientsRecovery of RV failure in PAH after lung transplantationLung donor characteristics as risk factors for PGD and CLADMolecular biomarkers as potential targets for therapeutic strategies after lung transplantationCorrelation of the incidence of acute rejection with the non-invasive blood transcriptional assay (SORT)Weight-to-height ratio as a predictor for CLAD and overall survival after lung transplantationCytokines and inflammatory variables in lung-transplanted recipientsAMR in lung transplantation: treatment and risk factorsCLAD subtypes, BOS and RAS, defined by computed tomography volumetry*AMR* antibody-mediated rejection, *CLAD* chronic lung allograft dysfunction, *BOS* bronchiolitis obliterans syndrome,*PGD*primary graft dysfunction, PTDM post-transplantation diabetes mellitus, *RAS* restrictive allograft syndrome

Clinical Assessment {#Sec8}
-------------------

All assessments and visits are shown in Table [4](#Tab4){ref-type="table"}. All the obtained data must be supported in the patient's medical records, i.e., source documentation, and subsequently stored in an electronic case record form (eCRF). Management of immunosuppressive regime of the ScanCLAD study is outlined in Table [5](#Tab5){ref-type="table"}. Azithromycin will not be performed as prophylaxis treatment, only when CLAD is suspected or diagnosed.Table 4Assessment schedulePeriodPeriod 1Period 2Visit12345678910Week/monthPre-LTxLTxW1W4M3M6M9M12M24M36Informed consentxInclusion/exclusionxxRandomizationxDemographyxGeneral medical historyxTransplantation informationxBackground donorxProtocol biopsyxxxHLA typingxHLAab/DSA (stored)xxxxxxxVital signsxxxxxxxxxxLung function test Spiro, DLCO, VOLxxxxxxxx6 min walk testxxxxQuality of lifexxxxLaboratory test Hematology/biochemistryxxxxxxxxxx Lipid profilexxxxxViral serology and PCRxxxxxxxxFlow cytometry (T cell activation) & ImmunKnow^®^ assayxxxxxPregnancy testxUrinalysisxxxxxxxcGFRxxxxxxxmGFRxxxxxHR-CT scanxxxxxxDrug concentration Cya/Tac blood conc levelxxxxxxxx MPA blood conc levelxxEchocardiography in PAHxxxxxxDNA/RNA isolationXxxxxxTac pharmacokineticsxxOGTTxxxxxSORT analysisxxxxxxxxxWeight-to-height ratioxxxxxxxxCytokines and inflammatory variablesxxxxxx*LTx* lung transplantation, *W* week, *HLA* human leucocyte antigen, *ab* antibody, *DSA* donor-specific antibodies, *DLCO* diffusing capacity of the lung for carbon monoxide, *VOL* lung volumes, *PCR* polymerase chain reaction, *cGFR* calculated glomerular filtration rate, *mGFR* measured GFR, *HR-CT* high resolution computer tomography, *Cya* cyclosporine, *Tac* tacrolimus, *PAH* pulmonary arterial hypertension, *DNA* deoxyribonucleic acid, *RNA* ribonucleic acid, *OGTT* oral glucose tolerance testTable 5Immunosuppressive regime in the ScanCLAD trial. Patients will be randomized in a 1:1 ratio into two groups, A and BGroup A: cyclosporine A, MMF, and corticosteroids  Induction therapy: Thymoglobulin^®^ (1.5 mg/kg given immediately postoperatively). Antihistamine (Tavegyl^®^) or similar at a dose of 2 mg iv before induction therapy is initiated  Cyclosporine A: given orally pretransplant at a dose of 2--3 mg/kg    Continued postop day 1 (24 h postoperatively) at a dose of 3 mg/kg^2^, according to local practice and blood concentration: 0--3 months, 250--300; 3--6 months, 200--250; 6--12 months, 150--200; \> 12 months 100--150 ng/ml. Cyclosporine A will be administered twice daily  MMF target dose 2000 mg/day (1 g × 2)    Controlled by a single area under the curve (AUC) measurement on day 90 with a target AUC between 40 and 60 mg h/L and corrected accordingly  Corticosteroids    Day 0 (day of lung transplantation); 500 + 500 mg methylprednisolone iv before reperfusion, i.e., restoration of blood flow into the transplanted allograft    From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg/day 1--6 months; less than 0.1 mg/kg/day \> 3--6 monthsGroup B: tacrolimus (Advagraf^®^), MMF, and corticosteroids  Induction therapy: Thymoglobulin^®^ (1.5 mg/kg given immediately postoperatively). Antihistamine (Tavegyl^®^) or similar should be started at a dose of 2 mg iv before induction therapy is initiated  Tacrolimus (Advagraf^®^)    Tacrolimus should be given orally pretransplant at a dose of 0.05--0.1 mg/kg    Continued postop day 1 (24 h postoperatively) at a dose of 0.1--0.2 mg/kg/24 h. To allow tacrolimus blood concentrations to stabilize, Adport^®^ (or any tacrolimus galenic form) should be ordered BiD for the first 3--7 days, or prolonged if long ICU stay is required, and patient should be switched to the investigational drug Advagraf^®^ OD at the ward or just prior to being discharged from ICU, and subsequently managed according to blood concentration levels: 0--3 months, 10--14, 3--6 months, 8--12; 6--12 months, 8--10; \> 12 months, 6--8 ng/ml  MMF target dose 2000 mg/day (1 g × 2)    Controlled by a single AUC measurement day 90 with a target AUC between 40 and 60 mg h/L and corrected accordingly  Corticosteroids    Day 0; 500 + 500 mg methylprednisolone iv before reperfusion, i.e., restoration of blood flow into the transplanted allograft    From day 1: initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg/day 1--6 months; less than 0.1 mg/kg/day \> 3--6 months

Efficacy Measurements {#Sec9}
---------------------

The following efficacy variables will be obtained and recorded:*Lung function testing:* Experienced and skilled technicians in a specialized respiratory laboratory will perform the pulmonary function tests. The quality control and performance of spirometry, measurements of lung volumes, and carbon monoxide uptake (CO uptake), i.e., transfer factor or diffusing capacity (DLCO), are in accordance with the European recommendations \[[@CR8]--[@CR10]\]. Spirometry is performed on a rolling seal spirometer. The forced expiratory vital capacity (FVC) and forced expiratory volume in first second (FEV1) are taken as the highest of repeated recordings. Lung volumes, i.e., total lung capacity (TLC), functional residual capacity (FRC), and residual volume (RV), are obtained in a body plethysmograph. CO uptake is obtained by the single-breath method using standard equipment. Volume and gas concentration calibrations are checked daily. At visits 4 and 7 only spirometry will be performed without volumes or DLCO. The baseline value is defined as the mean of the two best FEV1 values post LTx, from which CLAD will be determined (and FVC will be used to discriminate between BOS and RAS) according to the most updated recommendations \[[@CR7]\].*Measured glomerular filtration rate (mGFR):* The mGFR is the best clinical estimate of renal function in health and disease, and correlates well with the clinical severity of renal function disturbances also after transplantation \[[@CR11]\]. GFR will be measured using Cr-EDTA clearance or iohexol clearance. The same method should be used throughout the study for a given patient.*Calculated glomerular filtration rate (cGFR):* The GFR calculated according to the MDRD (Modification of Diet in Renal Disease Study Group) method \[[@CR12], [@CR13]\] will be used as a secondary outcome measure in this study. The calculated GFR is expressed in ml/min per 1.73 m^2^.*Rejection episodes and graft loss:* All suspected rejection episodes will be recorded in the adverse event (AE) module in the eCRF, whether a biopsy was performed, whether follow-up biopsies were performed, whether anti-rejection therapy was administered, whether the acute rejection was confirmed or with final clinical diagnosis specified, and final clinical outcome.Biopsy-Proven Acute RejectionIn all suspected rejection episodes, a transbronchial biopsy will be done according to local practice prior to or at the latest within 24 h after the initiation of anti-rejection therapy. Biopsies will be read and interpreted by local pathologists. A biopsy-proven acute rejection will be defined as a biopsy graded A1--A4 or antibody-mediated rejection according to International Society of Heart and Lung Transplantation (ISHLT) classification \[[@CR14]\].Graft LossGraft loss is considered a serious adverse event (SAE) and should be reported in the SAE module, and the reason for graft loss should be recorded thoroughly.*Primary graft dysfunction:* Primary graft dysfunction (PGD) is defined according to ISHLT definition as pulmonary infiltrates and hypoxemia occurring in the first 72 h after transplantation \[[@CR15]\]. Because chest x-ray has a low sensitivity to detect interstitial changes in transplanted lungs, follow-up will include high-resolution computed tomography (HR-CT) on day 3 at definition of PGD and subsequent follow-up at months 3 and 12 where bronchoscopy with transbronchial biopsy (TBB) is available for correlation study. A validated scoring system, which has been used in a previous prospective study of PGD, will be applied \[[@CR16], [@CR17]\].*Measurements of inflammatory variables:* Cytokines and other inflammatory variable will be analyzed in plasma/serum enzyme immunoassays or Luminex multiplex assay. Serum and plasma samples will be taken before transplantation, at 1, 4, and 12 weeks, and at 6 and 12 months post-transplant and cryopreserved at − 80 °C for later analyses. All analyses will be performed at a central laboratory in Oslo, Norway. Standard inflammatory cytokines/chemokines and complement activation will be measured as previously described \[[@CR18]\].*Measurements of donor-specific antibodies:* The human leukocyte antigen (HLA) antibody status and the presence of donor-specific HLA antibodies (DSA) before transplantation and produced de novo at 4 weeks, 3 and 12 months, and 2 and 3 years post-transplantation will be analyzed using standard methodology already in use in the tissue typing lab at Sahlgrenska University Hospital. All tests will be performed in one laboratory to avoid interlaboratory variation. Collected samples will be stored at − 80 °C for additional analyses if new tests for other antigens appear on the market.*Functional assessments:* A 6-minute walk test (6MWT) is a functional test that may be performed in the hallway or on the treadmill in a standardized manner.*Quality of life assessments:* Two standardized questionnaires, EQ5D3L and The St. George's Respiratory Questionnaire (SGRQ), will be used. Measurements will be done prior to LTx and 1, 2, and 3 years after lung transplantation.*NODAT/PTDM:* New-onset diabetes after transplantation (NODAT) or post-transplantation diabetes mellitus (PTDM) \[[@CR19]\] will be assessed by oral glucose tolerance test (OGTT) pre-Tx and at 6, 12, 24, and 36 months after transplantation.

Results {#Sec12}
=======

Safety Assessment {#Sec13}
-----------------

Treatment with tacrolimus versus cyclosporine has been shown to be safe and comparable regarding early outcome such as rejection rates and early mortality, as outlined in our literature review \[[@CR20]\]. However, there are few comprehensive studies and data on long-term outcome, particularly on CLAD, is scarce.

Safety assessments will consist of monitoring and recording all infections, any malignancies, AEs, SAEs, and suspected unexpected serious adverse reactions (SUSARs), the regular monitoring of hematology, blood chemistry, physiological testing, and regular measurement of vital signs. To ensure patient safety, every SAE, regardless of suspected causality, occurring after the patient is randomized and until 4 weeks after the patient has stopped study participation must be reported to the sponsor within 24 h or at first possible weekday of learning of its occurrence, whichever comes first.

Sample Size and Power Calculation {#Sec14}
---------------------------------

In order to detect a difference in CLAD between the two treatment groups in the ScanCLAD study, we calculated our sample size according to the following assumptions: 2-year inclusion, 3-year follow-up, 80% power, and two-sided significance level of 5%. On the basis of these assumptions, the numbers needed were calculated as follows: CLAD incidence in CyA and Tac arm of 30% (BOS alone approximately 30% at 3 years \[[@CR4]\] with cyclosporine) and 15% (50% reduction was seen in the Treede study \[[@CR3]\] with Tac, although from 22% to 11%), respectively, and 30% censuring (early dropouts) which would require 121 patients in each arm, altogether 242 patients in the study.

Statistical Analyses {#Sec15}
--------------------

A statistical analysis plan (SAP) was written and approved by the ethics committees (EC). All analyses and tabulations will be performed using the latest release of Stata software statistical program (currently version 14.0). The analysis will be done when all patients have completed the trial at 36 months after LTx (or discontinued prematurely). Unless otherwise stated, all statistical tests will be two-sided and use the 5% level of statistical significance. Confidence intervals will be presented with 95% as the level of confidence. All summary statistics will be presented for the treatment groups. Frequency distributions will be provided for categorical variables and the two treatment groups will be compared with the chi-square or Fisher's exact test. Descriptive statistics of mean, standard deviation, minimum, median and maximum will be presented for continuous variables; comparison of the two treatment groups will be performed with suitable chosen two-sample tests. Time to event data including rates of affected patients will be assessed by Kaplan--Meier statistics and compared between the two groups with the log rank test. Cumulative incidence will also be analyzed by competing risk methods when competing risks are present and will be compared between the two groups with the Fine and Gray's test or similar test. Data from all centers that participate in this study will be combined.

### Populations for Analysis {#Sec16}

The enrolled patient (ENR) population will include all patients who signed an informed consent regardless of whether lung transplantation was performed or not.

The intention-to-treat (ITT) population will consist of all randomized patients. The ITT population will be analyzed following the ITT principle. However, this analysis is not the main analysis of the study, since some patients will inevitably be sent home without transplantation because of worsening of donor organ function or other reasons, explained by the fact that randomization occurs prior to transplantation. The ITT population will therefore include patients who never underwent transplantation or received study drug.

The most important populations of study to analyze are the following:The per protocol transplanted (PP~trans~) population will consist of all patients in whom transplantation was performed and who were randomized and treated with at least one dose of randomized treatment. The PP~trans~ population is also the safety population (SAF).The per protocol CLAD (PP~CLAD~) population (or full-analysis set population, FAS) will consist of all randomized patients who received at least one dose of any immunosuppressive therapy, underwent transplantation, and had at least one post-baseline assessment of the primary efficacy variable (CLAD). Randomized patients without data on the primary outcome variable will be excluded from this population.The per protocol drug (PP~drug~) population will consist of all ITT patients who did not show major deviations from the protocol procedures that may have an impact on the study outcome, remained on randomized study drug, and who have completed the treatment phase at 36 months according to protocol.

### Interim Analysis {#Sec17}

There will be no planned interim analysis initiated by the steering committee; however, if the data and safety monitoring board (DSMB) wants one performed it can be done blinded.

Data Management {#Sec18}
---------------

### Randomization {#Sec22}

The eCRF software creates the enrollment and randomization numbers at enrollment and randomization visits, respectively. Randomization is performed using a web-based system and patients are randomized in a 1:1 ratio to one of the two treatment groups. Two sets of randomization numbers will be prepared for stratified randomization: (1) patients with a diagnosis of cystic fibrosis and (2) patients without a diagnosis of cystic fibrosis.

### Site Monitoring {#Sec23}

During the study, a field monitor will visit the site regularly to check the completeness of patient records, the accuracy of entries in the eCRFs, the adherence to the protocol and Good Clinical Practice (GCP), and the progress of enrollment. Monitoring standards are followed and all checks of the consistency of the source data with the CRFs are performed according to the study-specific monitoring plan.

### Data Collection {#Sec24}

Gothia Forum, a non-profit organization associated with Gothenburg University and Sahlgrenska University Hospital, assists the sponsor (GD) and all PIs in organizing the study according to GCP rules. The study database is placed on a central internet server. Designated investigator staff will enter the data required by the protocol into the database. Automatic validation programs check for data discrepancies in the eCRFs and, by generating appropriate error messages, allow modification or verification of the entered data by the investigator staff before being saved in the database.

### Database Management and Quality Control {#Sec25}

Gothia Forum will review the eCRFs entered by investigational staff for completeness and accuracy and instruct the site personnel to make any required corrections or additions.

Discussion {#Sec19}
==========

In brief, CLAD is currently defined as an irreversible drop in FEV1 to below 80% of baseline FEV1 after LTx. In recent studies RAS seems to account for approximately 30% of all CLAD and BOS for the remaining 70% \[[@CR6]\]. For qualifying as RAS, lung function measurements also need to show restrictive physiology, defined as an irreversible decline in TLC to below 90% of the baseline TLC \[[@CR6], [@CR7], [@CR21]\]. CLAD is one of the most common causes of long-term deaths according to the ISHLT registry \[[@CR22]\].

A Cochrane review on tacrolimus use was performed 6 years ago by the Copenhagen group and showed that tacrolimus may be superior to cyclosporine regarding BOS, treatment withdrawal, and arterial hypertension, but may be inferior regarding development of diabetes. No difference in mortality and acute rejection was observed between patients treated with tacrolimus and cyclosporine \[[@CR20]\].

CNIs, such as tacrolimus or cyclosporine, are the cornerstones of immunosuppressive protocols worldwide in LTx. There are well-known side effects of these drugs, such as nephrotoxicity and an increased incidence of diabetes, cardiovascular morbidity, and malignancy. All centers are using CNIs after LTx; however, in the last decade a switch has occurred worldwide from cyclosporine to tacrolimus, according to the ISHLT registry \[[@CR4]\]. This change has occurred even though there have been no real proof-of-concept studies confirming that tacrolimus is superior to cyclosporine with respect to long-term survival after LTx. Controversy has existed whether or not tacrolimus would result in fewer rejections over time as indicated by registry data but so far not shown in properly designed studies in LTx patients. Therefore, cyclosporine is still the CNI of choice in all Scandinavian lung transplant programs. However, recently a European--Australian prospective randomized study showed that tacrolimus had a lower incidence of BOS in LTx, after a 3-year follow-up \[[@CR3]\]. The incidence of BOS decreased from approximately 21% to 11% at 3 years, despite the fact that considerably more patients crossed over from the cyclosporine group to the tacrolimus group than vice versa. However, there was no significant difference in survival between the groups, which might have been related to the high rate of crossover. We expect a lower crossover rate in the Scandinavian study, compared to Treede et al., which may impact survival if there is a true difference between the studied drugs. In addition, our aim is to include all adult patients eligible for de novo double lung transplantation and without exclusion criteria, in order to have minimal selection bias and achieve a generalizable study in lung transplantation. The ScanCLAD study has caused synchronized programs in all Scandinavian lung transplant centers (five centers in four countries) both with regard to treatment and examinations. We stand more united with more than 150 lung transplantations per year.

In conclusion, we believe that clinical equipoise still exists regarding which CNI that should be used after lung transplantation, and that registry data and the few studies available suffer from bias. In an attempt to improve the low level of evidence, we have begun an investigator-initiated RCT regarding the preferred CNI after LTx.

Strengths and Limitations of the Study {#Sec20}
--------------------------------------

This multicenter, randomized, open-label study called the ScanCLAD study aims to include most adult patients undergoing double lung transplantation, and hopefully will add evidence on which CNI will result in less CLAD after lung transplantation. Not many studies have been conducted on the choice of CNI in de novo lung-transplanted patients, and this one is also designed with a number of substudies. The strengths of this study are that in a randomized controlled fashion two drugs preventing rejection are compared regarding long-term CLAD at 3 years among five centers having the same protocol after lung transplantation. Unlike previous studies, ours will also comply with the modern definition of CLAD. Furthermore, we will have an adjudication committee regarding the main outcome CLAD. Potential limitations are the usual ones associated with a randomized controlled study and also that it is not a double-blind study, and therefore may introduce bias.

Current Study Status {#Sec21}
--------------------

The study was initiated in November 2016 in Gothenburg, and subsequently all other sites were started in sequence with the last one up and running in July 2017. Since then 227 patients have been randomized (Fig. [2](#Fig2){ref-type="fig"}). Four amendments to the study protocol have been filed so far and approved by the EC in all countries. The study is followed by a DSMB group, consisting of Andrew Fisher, Jens Gottlieb, Eric Verschuuren, and Hans Wedel, that oversees the study and meets every 6 months. We are currently meeting our expected inclusion rate and anticipate randomizing the last patient sometime after the summer of 2019. The planned last patient visit will be in 2022.Fig. 2Randomized patients at the end of April 2019 and stratified by center in the ScanCLAD study. GOT = Gothenburg, Sweden; Lund = Lund, Sweden; CPH = Copenhagen, Denmark; HELS = Helsinki, Finland; and OSLO = Oslo, Norway
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